---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-025698"
form_type: "8-K/A"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:48:17.849559+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma FY2022 revenue $970K (+173%) but net loss widens to $16.3M

## Summary
- Revenue $969,783 (up 173% from $355,797) driven by contract services with Rgene.
- Net loss $16.3M vs $12.0M in 2021; operating expenses $15.8M (up $3.7M).
- Cash dropped to $85K from $5.8M; working deficit of $2.8M.
- Pipeline: Vitargus Phase II expected completion end of 2023; ABV-1505 ADHD enrollment ongoing.
- ABV-1601 Phase I at Cedars-Sinai initiated; ABV-1504 MDD meeting with FDA for Phase III.

## SEC filing metadata
- accession: 0001213900-23-025698
- form_type: 8-K/A
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/0001213900-23-025698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/ea176287-8ka_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-025698
- JSON: https://secwatch.observer/filing/0001213900-23-025698.json
- Plain text: https://secwatch.observer/filing/0001213900-23-025698.txt

## Key facts
- Earnings Releases
  ABVC BIOPHARMA, INC. reported the fiscal year ended December 31, 2022 results: revenue $969,783, net income $16,312,374.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $969,783
  - Net income: $16,312,374
  - Result: reported results
  source text: and operating results for the fiscal year ended December 31, 2022. Full Year 2022 Financial Results All comparisons are made on a year-over-year basis. ● Revenues . We generated $969,783 and $355,797 in revenues for the years ended December 31, 2022 and 2021, respectively. The increase of $613,986, or approximately 173%, was primarily caused by the increase in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/0001213900-23-025698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.